logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for

CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences, Inc., announced the news about the granted U.S. Patent No. 10,000,772 (“the ‘772 patent”) by the U.S. Patent and Trademark Office (USPTO). This patent covers methods of using optimized guide RNA formats (including single...

Read More

June 20, 2018

0

Atossa Genetics Has Promising News

Atossa Genetics Promising News for Endoxifen Atossa Genetics ( ATOS )   has promising news from a Phase 2 trial of its topical Endoxifen for mammographic breast density ( MBD ) reduction.     Preliminary analysis from a recently completed Phase...

Read More

June 27, 2019

0

Reasons for RegenxBio’s outperformance and some other Prohost big winners

On May 25, in Prohost Letter Issue #421 , we wrote about RegenxBio (RGNX) , which from behind the scenes it created several gene therapy products that are being used by AveXis , a firm that was recently acquired by...

Read More

June 20, 2018

0

About the Prohost Portfolio Tables

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks  Forty-Seven ( FTSV ) and   IVERIC bio ( ISEE ) have continued to outperform since the day they managed to prove their lead products' safety and efficacy...

Read More

December 5, 2019

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in Hemophilia Patients Sangamo Therapeutics ( SGMO ) and Pfizer ( PFE ) updated results from the Phase 1/2 Alta study, evaluating investigational SB-525 gene...

Read More

July 8, 2019

0

Are Illumina's 2019 Challenges Transitory?

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina ( ILMN )  stock dropped 16% following the firm's announcement of preliminary revenue for the second quarter of the fiscal year 2019 and updated its 2019 revenue guidance. According to the...

Read More

July 12, 2019

0

Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ ( NKTR ) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology ( ASH ) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson...

Read More

December 11, 2019

0

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis ( EXEL ) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021;...

Read More

July 15, 2019

0

Incyte’s promising trial results and its plans to accelerate its future growth

Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi ® ) in combination with corticosteroids for patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint , with a 55%...

Read More

June 21, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 76
  • 77
  • 78
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy